A further 8 million SEK to support clinical studies relating to COVID-19

The six regional nodes within Clinical Studies Sweden will receive an additional 8 million SEK in total, or 1.3 million SEK each, to further expand their abilities to support clinical studies linked to COVID-19.

Earlier this year, the regional nodes within Clinical Studies Sweden received a total of 12 million SEK from the Swedish Research Council. Now they will receive a further 8 million SEK to support clinical studies linked to COVID-19.

The initiative follows from the Swedish Research Council’s mandate to temporarily reinforce the activities within Clinical Studies Sweden to increase the opportunities for clinical researchers in Sweden to conduct clinical studies linked to the disease COVID-19. The funding is part of the 100 million SEK that the Swedish Research Council, in collaboration with Vinnova, has to allocate to research and innovation that can contribute to stopping the spread of COVID-19 and preventing future pandemic outbreaks.

The regional nodes offer various types of support to researchers in their work on clinical studies. Examples include help with study protocols, permit applications, data management and education.

Read more about the nodes on External link.

A map showing the six healthcare regions in the collaboration Clinical Studies Sweden.




  1. Research overview for clinical therapy research

    You are now able to comment on the contents of the preliminary research overview for clinical therapy research. Please read the instructions and submit your comments no later than 12 October.

  2. The Swedish Research Council establishes national support and advice on health data

    Increased knowledge, national coordination and regular mappings of unclear areas and obstacles. This is the way forward for improving the utilisation of health data for research and innovation. We are now beginning the work of establishing national s...

  3. High quality research into post-COVID syndrome and COVID-19 vaccines

    High quality and good opportunities to contribute to societal benefits summarise the applications approved within the research initiatives for post-COVID syndrome and follow-up studies of COVID-19 vaccines. In relation to studies of COVID-19 vaccines...